Research and Markets has announced the addition of the "Pre-Eclampsia - Pipeline Review, H2 2016" report to their offering.
'Pre-Eclampsia - Pipeline Review, H2 2016'; Pre-Eclampsia pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities Institutes.
Furthermore, the publisher says; Pre-Eclampsia Pre-eclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, often the kidneys. Signs and symptoms include severe headaches, decreased urine output, nausea or vomiting, shortness of breath, caused by fluid in lungs, impaired liver function, upper abdominal pain, usually under your ribs on the right side.
The report 'Pre-Eclampsia - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/c2dj29/preeclampsia
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005864/en/Business Wire
Last updated on: 12/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.